Aion Therapeutic Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Graham Simmonds Jr.
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 45 Sheppard Avenue East Vancouver BC Canada M2N 5W9
- IPO Date
- Apr 21, 2021
- Website
- aiontherapeutic.com
- Similar Companies
- Business
- Aion Therapeutic Inc. (CSE: AION, OTC: ANTCF) is a Canada-based health and wellness company focused on research, development, and commercialization of innovative therapeutics and filtration solutions. Incorporated in 2011 and headquartered at 700 West Georgia Street, Vancouver, British Columbia, the company operates primarily through its subsidiary AI Pharmaceuticals Jamaica Limited, leveraging Jamaica's regulatory environment for medical cannabis and psychedelic mushrooms; it generates revenue from the United States and targets global markets. Aion Therapeutic applies artificial intelligence and data mining techniques to develop patentable combinatorial formulations combining compounds from medical cannabis (including cannabinoids), medicinal and psychedelic mushrooms (such as psilocybin), fungi, natural psychedelics, and other medicinal plants into pharmaceuticals, nutraceuticals, and cosmeceuticals for treating conditions including cancer (such as breast and bladder cancers), major depressive disorder, addiction (opioid, alcohol, tobacco), post-traumatic stress disorder, anxiety, viral infections, obesity, and inflammatory disorders; through its Aion International Center for Psychedelic Psychiatry, it provides specialized psilocybin-based treatments; following the December 2023 acquisition of Toppen Health Inc., a US-based water filtration provider, Aion offers the UltraSafe, UltraHome, and commercial series systems incorporating MicronGuard technology for mechanical, membrane, adsorption, silver infection control, ion exchange, and chemical filtration to remove contaminants like bacteria, viruses, PFAS, heavy metals, pharmaceuticals, and pesticides, with dedicated dental division solutions for Dental Support Organizations and practices, consumer under-sink and whole-home units, portable bottle filters, and B2B municipal/industrial applications serving homes, offices, clinics, agriculture, remote communities, and underserved regions worldwide. Recent developments include the opening of the Aion International Center for Psychedelic Psychiatry, multiple US patent filings (including five in 2020 and four in 2021 for cannabis-mushroom combinations and mushroom-only cancer treatments, expanding its portfolio to at least nine), the completed acquisition of Toppen Health Inc. for CAD $10 million in shares (with potential US $2 million earn-out through April 2025), non-brokered private placements (including first tranche closing in September 2024 and updates in 2025), a change of auditor in June 2025, hiring of a contract research organization for Toppen operations, revocation of a management cease trade order, engagement of market-making services, and director changes.
Aion Therapeutic Announces Change of Auditor
Aion Therapeutic Provides Update on Non-Brokered Private Placement Offering of Units
Aion Therapeutic Announces Revocation of MCTO
Aion Therapeutic Provides Bi-Weekly MCTO Status Update
Aion Therapeutic Hires CRO for Toppen Health; Announces Director Resignation
Aion Therapeutic Announces Non- Brokered Private Placement Offering of Units
Aion Therapeutic Provides Bi-Weekly MCTO Status Update
Aion Therapeutic Provides Bi-Weekly MCTO Status Update
Aion Therapeutic Announces Closing of First Tranche of Non-Brokered Private Placement Offering of Units
Aion Therapeutic Provides Bi-Weekly MCTO Status Update
Aion Therapeutic Announces Grant of Management Cease Trade Order
Aion Therapeutic Announces Non-Brokered Private Placement Offering of Units
Aion Therapeutic Reports Delay in Filing 2024 Annual Financial Statements
Aion Therapeutic Secures Licensing Agreement for Molecular Iodine Technology
Aion Therapeutic Completes Non-Brokered Private Placement Offering of Units
Aion Therapeutic Announces Proposed Non- Brokered Private Placement Offering of Units
Aion Therapeutic Responds to First-Ever U.S. Drinking Water Standard Making PFAS Removal a Top Priority
Aion Therapeutic Engages Independent Trading Group for Market Making Services
Aion Therapeutic Announces Closing of Toppen Health Inc. Acquisition
Aion Therapeutic Announces Definitive Agreement to Acquire Toppen Health Inc.